MA53322A - Anticorps procoagulants améliorés - Google Patents

Anticorps procoagulants améliorés

Info

Publication number: MA53322A
Authority: MA; Morocco
Prior art keywords: procoagulant antibodies; enhanced procoagulant; enhanced; antibodies; procoagulant
Prior art date: 2018-08-01

Application number

MA053322A

Other languages

English (en)

Inventor

Jianhe Chen

Per J Greisen

Bjarne Gram Hansen

Mikkel Nors Harndahl

Eva Johansson

Laust Bruun Johnsen

Morten Grønbech Rasch

Anders Svensson

Karina Thorn

Zhiru Yang

Rong Zhou

Haisun Zhu

Henrik Østergaard

Original Assignee

Novo Nordisk As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2018-08-01

Filing date

2019-07-31

Publication date

2021-11-10

2019-07-31 Application filed by Novo Nordisk As filed Critical Novo Nordisk As

2021-11-10 Publication of MA53322A publication Critical patent/MA53322A/fr

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Hematology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Biophysics (AREA)
Chemical Kinetics & Catalysis (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Genetics & Genomics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

MA053322A 2018-08-01 2019-07-31 Anticorps procoagulants améliorés MA53322A (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
CN2018097834		2018-08-01
CN2018099339		2018-08-08
EP18193191		2018-09-07

Publications (1)

Publication Number	Publication Date
MA53322A true MA53322A (fr)	2021-11-10

Family

ID=67480228

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA053322A MA53322A (fr)	2018-08-01	2019-07-31	Anticorps procoagulants améliorés

Country Status (18)

Country	Link
US (1)	US20230058721A1 (fr)
EP (1)	EP3830135A1 (fr)
JP (3)	JP6761142B1 (fr)
KR (2)	KR102887629B1 (fr)
CN (3)	CN112513096B (fr)
AU (1)	AU2019313550B2 (fr)
CA (1)	CA3113797A1 (fr)
CL (2)	CL2021000186A1 (fr)
CO (1)	CO2021001046A2 (fr)
IL (1)	IL280239B2 (fr)
MA (1)	MA53322A (fr)
MX (1)	MX2021001064A (fr)
MY (1)	MY202203A (fr)
PE (1)	PE20211399A1 (fr)
PH (1)	PH12021550117A1 (fr)
SG (1)	SG11202100418PA (fr)
TW (1)	TWI716059B (fr)
WO (1)	WO2020025672A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN115052898B (zh) *	2020-01-30	2025-09-16	诺和诺德股份有限公司	双特异性因子viii模拟抗体
KR102868672B1 (ko) *	2022-03-02	2025-10-14	노보 노르디스크 헬스 케어 악티엔게젤샤프트	Fviii 모방 이중특이적 항체를 2주마다 1회 투여하는 방법
CN118786148A (zh) *	2022-03-02	2024-10-15	诺和诺德医疗保健公司	每周一次施用fviii模拟双特异性抗体的方法
KR102839278B1 (ko)	2022-03-02	2025-07-30	노보 노르디스크 헬스 케어 악티엔게젤샤프트	Fviii 모방 이중특이적 항체의 월 1회 투여 방법
KR102839225B1 (ko) *	2022-03-02	2025-07-29	노보 노르디스크 헬스 케어 악티엔게젤샤프트	Fviii 모방 이중특이적 항체의 주 1회 투여 방법
US12098400B2 (en)	2022-07-08	2024-09-24	Novo Nordisk A/S	Highly potent ISVD compounds capable of substituting for FVIII(A)
PE20251082A1 (es)	2022-07-08	2025-04-10	Novo Nordisk As	Compuestos de isvd altamente potentes capaces de sustituir al fviii(a)
KR20250000093A (ko)	2023-06-23	2025-01-02	노보 노르디스크 헬스 케어 악티엔게젤샤프트	Fviii 모방 이중특이적 항체의 격월 1회 투여 방법
GB202408056D0 (en) *	2024-06-06	2024-07-24	Cambridge Entpr Ltd	Anticoagulant protein molecules and uses thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5677425A (en)	1987-09-04	1997-10-14	Celltech Therapeutics Limited	Recombinant antibody
DK0979281T3 (da) *	1997-05-02	2005-11-21	Genentech Inc	Fremgangsmåde til fremstilling af multispecifikke antistoffer med heteromultimere og fælles bestanddele
AT411997B (de) *	1999-09-14	2004-08-26	Baxter Ag	Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate
US7297336B2 (en)	2003-09-12	2007-11-20	Baxter International Inc.	Factor IXa specific antibodies displaying factor VIIIa like activity
WO2005035754A1 (fr) *	2003-10-14	2005-04-21	Chugai Seiyaku Kabushiki Kaisha	Anticorps a double specificite de substitution de proteine fonctionnelle
AU2003271174A1 (en) *	2003-10-10	2005-04-27	Chugai Seiyaku Kabushiki Kaisha	Double specific antibodies substituting for functional protein
CA2603264C (fr) *	2005-04-08	2017-03-21	Chugai Seiyaku Kabushiki Kaisha	Substitution des anticorps de la fonction du facteur viii de coagulation sanguine
KR101962483B1 (ko) *	2010-11-17	2019-03-29	추가이 세이야쿠 가부시키가이샤	혈액응고 제viii 인자의 기능을 대체하는 기능을 갖는 다중특이성 항원 결합 분자
BR112014027952B1 (pt) *	2012-05-10	2022-06-21	Bayer Pharma Aktiengesellschaft	Anticorpos monoclonais humanos capazes de se ligarem ao fator de coagulação xi, seu uso, composição farmacêutica e medicamento os compreendendo, ácido nucleico que o codifica, bem como vetor
CN105705517A (zh) *	2013-11-07	2016-06-22	诺和诺德股份有限公司	用于治疗凝血障碍的新方法和抗体
TWI700300B (zh) *	2014-09-26	2020-08-01	日商中外製藥股份有限公司	中和具有第ｖｉｉｉ凝血因子（ｆｖｉｉｉ）機能替代活性的物質之抗體
AU2016248817A1 (en) *	2015-04-17	2017-08-17	F. Hoffmann-La Roche Ag	Combination therapy with coagulation factors and multispecific antibodies
CN110662770A (zh) *	2016-11-23	2020-01-07	比奥维拉迪维治疗股份有限公司	结合凝血因子ix和凝血因子x的双特异性抗体
KR20190112747A (ko)	2017-02-01	2019-10-07	노보 노르디스크 에이/에스	응고촉진 항체
US11220554B2 (en) *	2018-09-07	2022-01-11	Novo Nordisk A/S	Procoagulant antibodies

2019
- 2019-07-31 CN CN201980050877.2A patent/CN112513096B/zh active Active
- 2019-07-31 KR KR1020217022278A patent/KR102887629B1/ko active Active
- 2019-07-31 CN CN202310981355.2A patent/CN117384296A/zh active Pending
- 2019-07-31 IL IL280239A patent/IL280239B2/en unknown
- 2019-07-31 PE PE2021000121A patent/PE20211399A1/es unknown
- 2019-07-31 MY MYPI2021000234A patent/MY202203A/en unknown
- 2019-07-31 CN CN202310977964.0A patent/CN117343188A/zh active Pending
- 2019-07-31 EP EP19746091.8A patent/EP3830135A1/fr active Pending
- 2019-07-31 WO PCT/EP2019/070628 patent/WO2020025672A1/fr not_active Ceased
- 2019-07-31 CA CA3113797A patent/CA3113797A1/fr active Pending
- 2019-07-31 MA MA053322A patent/MA53322A/fr unknown
- 2019-07-31 SG SG11202100418PA patent/SG11202100418PA/en unknown
- 2019-07-31 JP JP2020506232A patent/JP6761142B1/ja active Active
- 2019-07-31 KR KR1020217004977A patent/KR102382743B1/ko active Active
- 2019-07-31 AU AU2019313550A patent/AU2019313550B2/en active Active
- 2019-07-31 MX MX2021001064A patent/MX2021001064A/es unknown
- 2019-08-01 TW TW108127371A patent/TWI716059B/zh active
2020
- 2020-03-04 JP JP2020036964A patent/JP7094314B2/ja active Active
2021
- 2021-01-15 PH PH12021550117A patent/PH12021550117A1/en unknown
- 2021-01-22 CL CL2021000186A patent/CL2021000186A1/es unknown
- 2021-01-29 CO CONC2021/0001046A patent/CO2021001046A2/es unknown
- 2021-11-10 US US17/522,949 patent/US20230058721A1/en active Pending
2022
- 2022-03-25 JP JP2022050042A patent/JP7355874B2/ja active Active
2025
- 2025-04-29 CL CL2025001281A patent/CL2025001281A1/es unknown

Also Published As

Publication number	Publication date
IL280239B1 (en)	2025-11-01
CN112513096B (zh)	2023-08-25
CN117384296A (zh)	2024-01-12
IL280239A (en)	2021-03-25
WO2020025672A9 (fr)	2020-04-23
SG11202100418PA (en)	2021-02-25
CN112513096A (zh)	2021-03-16
KR102887629B1 (ko)	2025-11-19
TWI716059B (zh)	2021-01-11
JP6761142B1 (ja)	2020-09-23
KR102382743B1 (ko)	2022-04-12
MY202203A (en)	2024-04-17
WO2020025672A1 (fr)	2020-02-06
EP3830135A1 (fr)	2021-06-09
KR20210091839A (ko)	2021-07-22
CA3113797A1 (fr)	2020-02-06
AU2019313550A1 (en)	2021-02-04
TW202007696A (zh)	2020-02-16
JP2022084858A (ja)	2022-06-07
PH12021550117A1 (en)	2021-10-04
MX2021001064A (es)	2021-04-12
CL2025001281A1 (es)	2025-08-22
IL280239B2 (en)	2026-03-01
JP7355874B2 (ja)	2023-10-03
KR20210040389A (ko)	2021-04-13
US20230058721A1 (en)	2023-02-23
JP2020530449A (ja)	2020-10-22
BR112021000823A2 (pt)	2021-04-13
JP7094314B2 (ja)	2022-07-01
JP2020115863A (ja)	2020-08-06
PE20211399A1 (es)	2021-07-27
CO2021001046A2 (es)	2021-04-30
CN117343188A (zh)	2024-01-05
AU2019313550B2 (en)	2024-02-08
CL2021000186A1 (es)	2021-07-02

Publication	Publication Date	Title
MA52884A (fr)	2021-04-21	Anticorps anti-il-11
MA53434A (fr)	2021-12-01	Anticorps anti-tigit
EP3903817A4 (fr)	2022-08-17	Nouvel anticorps anti-ccr8
MA52366A (fr)	2021-03-03	Anticorps anti-tl1a optimisés
EP3883970A4 (fr)	2022-03-30	Anticorps anti-b7-h3
MA49034A (fr)	2020-02-12	Anticorps anti-lag3
MA47694A (fr)	2021-05-19	Anticorps anti-tigit
MA47268A (fr)	2019-11-20	Anticorps anti-gpc3
MA46525A (fr)	2019-08-21	Anticorps anti-lag-3 et compositions
MA44659A (fr)	2021-04-14	Anticorps anti-tim-3 et compositions
EP3498840A4 (fr)	2020-05-06	Anticorps anti-lag-3
EP3442579A4 (fr)	2019-12-18	Anticorps anti-vista humain et utilisation associée
EP3423089A4 (fr)	2019-10-23	Anticorps anti-tigit
EP3684806A4 (fr)	2021-09-22	Nouveaux anticorps anti-cd3epsilon
MA44236A (fr)	2018-12-26	Anticorps anti-tgfbêta 2
MA52152A (fr)	2021-01-20	Anticorps
EP3492591A4 (fr)	2020-04-01	Anticorps anti-b7-h4
EP3617231A4 (fr)	2021-04-07	Anticorps anti-gpc-1
EP3526247A4 (fr)	2021-04-14	Anticorps anti-il1-rap
MA51134A (fr)	2021-03-24	Anticorps anti-alpha-synucléine
EP3399992A4 (fr)	2019-07-31	Anticorps autoréticulants
EP3831851A4 (fr)	2022-04-27	Anticorps anti-btla
EP3596126A4 (fr)	2021-03-03	Nouveaux anticorps anti-trkb
EP3484919A4 (fr)	2020-03-04	Anticorps anti-bêta-amyloïde
IL280239A (en)	2021-03-25	Improved procoagulant antibodies